Ahlam Badri, Dan Gratschev, Tove Johansson, Agneta Wikman, Tesfai Emahazion
{"title":"Discordant prenatal and postnatal RhD typing caused by a novel RHD frameshift variant (c.540del; p.Leu181CysfsTer48) in Swedish individuals.","authors":"Ahlam Badri, Dan Gratschev, Tove Johansson, Agneta Wikman, Tesfai Emahazion","doi":"10.1111/vox.70351","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Non-invasive prenatal testing (NIPT) for fetal RHD genotyping is widely used to guide anti-D prophylaxis, but discrepancies between predicted fetal RhD status and postnatal serological typing can occur due to variant RHD alleles. This study aimed to confirm and characterize a suspected novel exon 4 deletion in RHD using multiple molecular methods and to assess inheritance.</p><p><strong>Materials and methods: </strong>NIPT predicted an RhD-positive fetus in an RhD-negative pregnant woman, whereas postnatal serology showed an RhD-negative phenotype. Molecular analysis of RHD was performed using the RBC-Ready Gene CDE kit (Inno-Train, Kronberg, Germany), targeted next-generation sequencing (NGS) and Sanger sequencing in the family and in an unrelated RhD-negative woman.</p><p><strong>Results: </strong>Targeted NGS identified a single-nucleotide deletion in the RHD gene (c.540del), predicted to result in a frameshift and premature termination (p.Leu181CysfsTer48). Sanger sequencing confirmed the variant in the newborn and demonstrated paternal inheritance, with the father heterozygous for the deletion. The same variant was also identified in an unrelated RhD-negative woman of Swedish origin; notably, the newborn's father was also of Swedish origin.</p><p><strong>Conclusion: </strong>This case illustrates a limitation of current NIPT approaches, which detect RHD sequences but not gene functionality. Molecular follow-up is crucial in cases of discordant RhD typing.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70351","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Non-invasive prenatal testing (NIPT) for fetal RHD genotyping is widely used to guide anti-D prophylaxis, but discrepancies between predicted fetal RhD status and postnatal serological typing can occur due to variant RHD alleles. This study aimed to confirm and characterize a suspected novel exon 4 deletion in RHD using multiple molecular methods and to assess inheritance.
Materials and methods: NIPT predicted an RhD-positive fetus in an RhD-negative pregnant woman, whereas postnatal serology showed an RhD-negative phenotype. Molecular analysis of RHD was performed using the RBC-Ready Gene CDE kit (Inno-Train, Kronberg, Germany), targeted next-generation sequencing (NGS) and Sanger sequencing in the family and in an unrelated RhD-negative woman.
Results: Targeted NGS identified a single-nucleotide deletion in the RHD gene (c.540del), predicted to result in a frameshift and premature termination (p.Leu181CysfsTer48). Sanger sequencing confirmed the variant in the newborn and demonstrated paternal inheritance, with the father heterozygous for the deletion. The same variant was also identified in an unrelated RhD-negative woman of Swedish origin; notably, the newborn's father was also of Swedish origin.
Conclusion: This case illustrates a limitation of current NIPT approaches, which detect RHD sequences but not gene functionality. Molecular follow-up is crucial in cases of discordant RhD typing.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.